Asco 2025 · Posters · Cáncer Genitourinario Volver

CÁNCER GENITOURINARIO

  • Próstata, testículo y pene
Manuel Pedregal, MD

Survival outcomes of patients with mNSGCTs with and without teratoma in the primary tumor: An international retrospective study.

Manuel Pedregal, MD

Hospital Universitario Fundación Jiménez Díaz, Madrid.

playAcceso
Lola Rodríguez Nogueira, MD

A novel prognostic model to optimize the timing of docetaxel (Doc) following an androgen receptor pathway inhibitor (ARPi) in metastasic castration-resistant prostate cancer (mCRPC).

Lola Rodríguez Nogueira, MD

Oncology Department, Hospital Universitario 12 de Octubre, Madrid

playAcceso
David Olmos, MD, PhD

Impact of somatic/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume.

David Olmos, MD, PhD

Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid.

playAcceso
  • Riñón y Vejiga
Elena Sevillano, MD

Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.

Elena Sevillano, MD

HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Laboratorio de Innovación en Oncología, Instituto de Investigación Sanitaria HM Hospitales

playAcceso
Cristina Suárez Sr, MD, PhD

Efficacy and safety of second-line cabozantinib ± atezolizumab for patients with advanced renal cell carcinoma after progression on immuno-oncology combinations: Subgroup analysis of CONTACT-03.

Cristina Suárez Sr, MD, PhD

Medical Oncology, Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus

playAcceso
Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo